Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.
Johnson & Johnson’s newly authorized Covid-19 vaccine started shipping and the company’s top executive said on March 1 that Americans should be able to receive the single-dose shot within 24 to 48 hours, adding a third vaccine in the United States.
Pipeline Report 2021: COVID-19 Edition
Annual Reports, AstraZeneca, Bayer, BioNTech, BNT162b2 (Pfizer and BioNTech), CanSino Biologics, Clinical Trials, Clover Biopharmaceuticals, Clover Biopharmaceuticals, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, CureVac, Eli Lilly, February 2021, Gamaleya Research Institute, Gilead, GlaxoSmithKline, Immunology Companies, Inovio Pharmaceuticals, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Med Ad News, Merck, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Novavax, Oxford University, Pfizer, R&D, Sanofi, Sinopharm, Sinovac, Special Reports, Sputnik V vaccine, The Lancet, Therapeutics, Top 10 Pipelines, Top 10 Pipelines To Watch, Vaccine Companies, Valneva, Vir BiotechnologyAs the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.